ect-001-cb
Cell therapyexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2019 (NCT03913026)
Timeline
Indications
Mechanism of action
- leukocytesSupplementation
leukocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301866 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2025 | Ciusss de L'Est de l'Île de Montréal, Stem Cell Network |
| NCT04990323 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2021 | ExcellThera, Memorial Sloan-Kettering Cancer Center |
| NCT04594031 | Phase 1 | Dec 1, 2020 | California Institute for Regenerative Medicine (CIRM), ExcellThera |
| NCT04103879 | Phase 2 | Sep 30, 2019 | ExcellThera, University of Washington |
| NCT03913026 | Phase 2 | Apr 30, 2019 | Ciusss de L'Est de l'Île de Montréal, ExcellThera, Hopital de l'Enfant-Jesus, McGill University, Stem Cell Network |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ExcellThera | For profit | 4 | 3 | 2 | 2019 |
| Ciusss de L'Est de l'Île de Montréal | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Stem Cell Network | Academic/Hospital | 2 | 0 | 1 | 2019 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Hopital de l'Enfant-Jesus | Academic/Hospital | 1 | 0 | 1 | 2019 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1